Electromed, Inc.

What they do

Electromed makes the SmartVest System, a programmable air pulse generator with a therapy garment and hose that delivers high frequency chest wall oscillation to clear retained airway secretions. The company primarily uses a direct-to-patient and provider model: it obtains clinician referrals, processes insurance claims, delivers the device to patients' homes and trains them on use, which the filing says disintermediates the traditional home medical equipment channel and captures both manufacturer and distributor margins. It also sells into the acute care setting for post-surgical, intensive care or lung-infection patients. SmartVest has been marketed since 2000 for bronchiectasis, cystic fibrosis and neuromuscular conditions such as cerebral palsy and ALS.

Revenue drivers

• Direct homecare — The core business: HFCWO devices placed with patients at home, with Electromed billing insurers. FY2026 direct homecare revenue was $66.6 million, up 16.3% from $57.3 million, and represented the overwhelming majority of total revenue. Growth was attributed to more direct sales representatives, higher productivity and higher net revenue per approval.
• Non-homecare — Sales into the acute care setting and other non-homecare channels. FY2026 revenue was $7.2 million, up $0.5 million or 6.7% from $6.7 million. This is the smaller revenue line.
• Sales force productivity — Electromed averaged 58 homecare field sales representatives in FY2026, and homecare revenue per weighted average direct sales representative was $1,145,000. The company said this exceeded its target range of $1,000,000 to $1,100,000 for the year.

Recent performance

FY2026 net revenue rose 15.3% to a record $73.8 million from $64.0 million, with operating income up 43.7% to $13.9 million, or 18.8% of net revenues. Net income was $11.3 million, or $1.30 per diluted share, versus $7.5 million, or $0.85 per diluted share, in FY2025. In Q4 FY2026, net revenue increased 11.6% to a record $19.4 million, operating income rose 25.8% to $3.8 million, or 19.7% of net revenues, and net income rose 54.3% to $3.4 million, or $0.39 per diluted share. Gross margin was 78.7% in Q4 FY2026 versus 78.3% a year earlier, helped by higher net revenue per device. Cash provided by operations was $9.7 million in FY2026 versus $11.4 million in FY2025.

Strategy

Electromed is investing in its sales force, systems and bronchiectasis market development, and management points to approximately 800,000 diagnosed bronchiectasis patients who could benefit from SmartVest. The company repurchased $3.9 million of its common stock during FY2026. In the Q4 release, management cited $20.5 million in cash and said the balance sheet positions Electromed for durable long-term growth. The direct-to-patient and provider model remains central, with the company continuing to add direct sales representatives and reimbursement and sales support staff to handle higher patient referrals.

Risks

• Payer and reimbursement concentration — Electromed's direct model depends on billing private insurance and federal or state government programs on behalf of patients, so coverage and payment rate changes could pressure revenue per approval.
• Receivables and collections — The March 31, 2026 balance sheet showed accounts receivable of $28.3 million, larger than quarterly revenue, reflecting the claims-processing model and the time it takes to collect from insurers.
• Sales force execution — Growth has been attributed to adding sales representatives and increasing productivity, so failure to recruit, retain or ramp reps would slow the direct homecare business.
• Dependence on a single platform — Revenue comes from the SmartVest System and related garments and support services, so competitive or clinical developments affecting HFCWO therapy could affect the whole business.

Outlook

The 8-K filed 2026-08-25 reported FY2026 results and included the earnings release with management commentary; the excerpts do not contain formal revenue or earnings guidance for FY2027. Management said FY2026 marked the 15th consecutive quarter of year-over-year revenue and profit growth and described the company as well-positioned for long-term growth and value creation. It also cited strategic investments in the sales force, systems and bronchiectasis market development.